Lamivudine: all 230 studies that test it
Page 1 of 3. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingNCT07792096Phase 3
- Lamivudine as a Novel Clinical Effort for Rett SyndromeEnrolling by invitationNCT07640503Phase 2
- Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir RegimensNot yet recruitingNCT07631897Phase 4
- A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentRecruitingNCT07393659Phase 3
- Efficacy and Safety of Doravirine in the Rapid InitiationRecruitingNCT07357584Phase 4
- Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-UpRecruitingNCT07138144Phase 4
- Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral ExperienceRecruitingNCT07031063Phase 4
- Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in MexicoRecruitingNCT06907056Phase 4
- Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTIRecruitingNCT06602622Phase 4
- Antiviral Therapy in Infants With HBV InfectionNot yet recruitingNCT06503796Phase 4
- STARLITE for Unresectable High-Grade GliomasRecruitingNCT06428045Phase 1
- DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 InfectionRecruitingNCT06203132Phase 3
- Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung CancerRecruitingNCT04696575Phase 2
- A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAFCompletedNCT05911360Phase 3Results posted
- Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3CompletedNCT04880395Phase 4Results posted
- Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's DiseaseCompletedNCT04552795Phase 1/2Results posted
- Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender WomenCompletedNCT04283656Phase 1Results posted
- Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)CompletedNCT04021290Phase 3Results posted
- Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected AdultsCompletedNCT03945981Phase 3Results posted
- Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected AdolescentsCompletedNCT03682848Phase 3Results posted
- Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)CompletedNCT03446573Phase 3Results posted
- Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAMCompletedNCT03311945Phase 3Results posted
- Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)CompletedNCT03272347Phase 2Results posted
- Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV InfectionCompletedNCT03205566Phase 4Results posted
- A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal CancerCompletedNCT03144804Phase 2Results posted
- Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and LamivudineCompletedNCT03078556Phase 1Results posted
- An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)CompletedNCT02831764Phase 3Results posted
- An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)CompletedNCT02831673Phase 3Results posted
- Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With OsteopeniaCompletedNCT02652793Not applicableResults posted
- A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy VolunteersCompletedNCT02634073Phase 4Results posted
- Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 PatientsCompletedNCT02582684Phase 2Results posted
- Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)CompletedNCT02403674Phase 3Results posted
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)CompletedNCT02397096Phase 3Results posted
- Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV InfectionCompletedNCT02384395Not applicableResults posted
- Safety & Efficacy of Dual Therapy With Raltegravir/LamivudineCompletedNCT02284035Phase 3Results posted
- A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant PhaseCompletedNCT02263079Phase 3Results posted
- Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)TerminatedNCT02116660Phase 2Results posted
- A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)CompletedNCT01910402Phase 3Results posted
- Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TCTerminatedNCT01620944Phase 3Results posted
- Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child TransmissionCompletedNCT01618305Phase 4Results posted
- Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral SuppressionCompletedNCT01387022Not applicableResults posted
- Lactic Acidosis During Entecavir(ETV)TreatmentTerminatedNCT01354652Phase 4Results posted
- Study of Options for Second-Line Effective Combination Therapy (SELECT)CompletedNCT01352715Phase 3Results posted
- Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging StrategyTerminatedNCT01338025Phase 4Results posted
- A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)CompletedNCT01095835Phase 3Results posted
- KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive SubjectsCompletedNCT00549198Phase 4Results posted
- Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 InfectionCompletedNCT00440947Phase 3Results posted
- Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, KenyaTerminatedNCT00427297Phase 3Results posted
- Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant VirusCompletedNCT00410202Phase 3Results posted
- Antiretroviral Therapy for Advanced HIV Disease in South AfricaCompletedNCT00342355Phase 4Results posted
- Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIVCompletedNCT00270296Phase 2Results posted
- Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at BirthCompletedNCT00102960Phase 3Results posted
- A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)CompletedNCT00100048Phase 2Results posted
- Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During PregnancyCompletedNCT00099632Phase 2Results posted
- Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV TransmissionCompletedNCT00099359Phase 3Results posted
- Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/LamivudineCompletedNCT00098293Phase 3Results posted
- Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited SettingsCompletedNCT00084136Phase 4Results posted
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsCompletedNCT00074581Phase 3Results posted
- Lamivudine and Adefovir to Treat Chronic Hepatitis BCompletedNCT00023309Phase 2Results posted
- A Study of Exercise and Pharmacologic Intervention on Systemic InflammationActive, not recruitingNCT07058974Phase 1
- Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South AfricaActive, not recruitingNCT07006246Phase 4
- A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)CompletedNCT06811246Phase 1
- A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)Active, not recruitingNCT06519357Phase 2
- Lamivudine for Solid TumorsActive, not recruitingNCT06494579Phase 1/2
- B/F/TAF to DTG/3TC Switch StudyActive, not recruitingNCT06444620Phase 3
- Lamivudine and Plasma Markers of Inflammation in Retinal DetachmentTerminatedNCT06056596Early Phase 1
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyActive, not recruitingNCT05979311Phase 3
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral TherapyCompletedNCT05917509Phase 3
- Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot StudyWithdrawnNCT05295394Phase 4
- Triumeq in Amyotrophic Lateral SclerosisTerminatedNCT05193994Phase 3
- Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected IndividualsCompletedNCT04904406Phase 4
- Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)Active, not recruitingNCT04826562Phase 4
- Inhibition of Reverse Transcription in Aicardi-Goutières SyndromeCompletedNCT04731103Phase 2
- Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping TestCompletedNCT04549467Phase 4
- ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI ResistanceStatus unknownNCT04429152Phase 3
- DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years OldActive, not recruitingNCT04337450Phase 2/3
- Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral DrugsCompletedNCT04302896Early Phase 1
- ANRS 12372 MODERATO StudyCompletedNCT04022967Phase 3
- Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive InterventionCompletedNCT03870438Phase 3
- Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEVStatus unknownNCT03869944Phase 2
- Body Composition Sub-study of the D2EFT TrialCompletedNCT03675815Phase 4
- Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.Status unknownNCT03539224Phase 2
- Dual Obstructive Sleep Apnea TherapyStatus unknownNCT03435731Not applicable
- Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current RegimenTerminatedNCT03333083Phase 3
- Optimization of Antiretroviral TherapyCompletedNCT02935075Phase 4
- Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected SubjectsCompletedNCT02770508Phase 4
- Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose CombinationsCompletedNCT02738931Phase 1
- Antiretroviral Regime for Viral Eradication in NewbornsCompletedNCT02712801Phase 4
- Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject DrugsTerminatedNCT02659761Phase 4
- ART Drug Dosage Adjustment in HIV-infected PopulationCompletedNCT02632474Phase 4
- Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet of 150 mg in Healthy VolunteersCompletedNCT02604004Phase 1
- Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance RegimenTerminatedNCT02566707Phase 2
- An Exploratory Study of RGT Strategy on Optimal NUC-experienced PatientsStatus unknownNCT02560649Phase 4
- A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)CompletedNCT02527096Phase 2
- Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical TrialCompletedNCT02431975Phase 4
- Early Infant HIV Treatment in BotswanaActive, not recruitingNCT02369406Phase 2/3
- Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral AgentsStatus unknownNCT02337127Phase 4
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple TherapyCompletedNCT02302547Phase 3
- Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active TuberculosisCompletedNCT02273765Phase 3
- Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without TipranavirCompletedNCT02249130Phase 2